Biomerica provides update on inFoods IBS expansion

Biomerica announced advancements in the roll out of the inFoods IBS product. Biomerica has expanded its reach with adoption by new offices in targeted regions, including the Southeast, Northeast and Midwest. The Company’s new salesforce has activated over 30 new Gastrointestinal physician groups, each with multiple GI physicians, and these new practices have begun recommending the Company’s revolutionary inFoods IBS Product to their IBS patients. Furthermore, the average increase in the number of physicians prescribing inFoods more than doubled each quarter over the past 12 months, reflecting growing adoption and trust within the GI medical community. The Company is also in discussions with large non-GI physician groups for utilization of the inFoods IBS test. This advances the strategic effort to expand to non-GI physicians to provide cutting-edge non-pharmaceutical care options for individuals grappling with chronic IBS conditions. This continued expansion demonstrates growing recognition and adoption of the inFoods IBS test in the medical community, broadening Biomerica’s influence in providing innovative solutions for irritable bowel syndrome while positioning the Company for product revenue growth over the coming quarters. Biomerica has also been issued notices of allowance on five new patents in Japan, Canada and the EU, for a total of 25 pending/issued patents worldwide. These allowed/issued patents cover the Company’s inFoods Technology and validate the novelty of this technology.